PILMA Applauds Senate’s Passage of S.3187 The FDA Safety and Innovation Act
May 24, 2012
The member companies and unions of the Pharmaceutical Industry Labor Management Association (PILMA) applaud the Senate’s 96 to 1 vote today in favor of passage of S. 3187, the Food and Drug Administration Safety and Innovation Act. Over the past 20 years, prescription drug user fees have been a key component in ensuring that the United States efficiently and safely brings new medicines to market, and extending the user-fees program will keep America at the forefront of new drug innovation and development well into the future. We congratulate Chairman Harkin and Ranking Member Enzi for their hard work in developing this measure and their effort in seeing it through the process in a way that protects the integrity of the underlying legislation. PILMA will to continue to support this legislation as it moves to the House, and we urge members on both sides of the aisle to support the integrity of this bill in order to ensure its swift consideration and final approval.